[
  {
    "ts": null,
    "headline": "AstraZeneca Stock Scores RS Rating Upgrade",
    "summary": "AstraZeneca ADR shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 80 to 83.",
    "url": "https://finnhub.io/api/news?id=a6bdc95763d16b3f6e8ac10b2bca3e91a0d4ed282d09b4845b98b90c25ca0d93",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741982520,
      "headline": "AstraZeneca Stock Scores RS Rating Upgrade",
      "id": 133184262,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "AstraZeneca ADR shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 80 to 83.",
      "url": "https://finnhub.io/api/news?id=a6bdc95763d16b3f6e8ac10b2bca3e91a0d4ed282d09b4845b98b90c25ca0d93"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly (NYSE:LLY) Sees 1.59% Rise As Jaypirca Secures Positive EU Opinion",
    "summary": "Eli Lilly (NYSE:LLY) recently announced several significant events, including promising trial results for baricitinib in treating severe alopecia areata and long-term efficacy data for EBGLYSS in atopic dermatitis. Additionally, the European Medicines Agency's positive opinion on Jaypirca for chronic lymphocytic leukemia marks a critical milestone. Meanwhile, the company is expanding its manufacturing capacity with plans to build four new sites in the U.S., promising substantial job creation...",
    "url": "https://finnhub.io/api/news?id=5420be4a870c13079b65675b3cdfd6ee173bf6bb8e2c85ee7f971434d15bdf85",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741974075,
      "headline": "Eli Lilly (NYSE:LLY) Sees 1.59% Rise As Jaypirca Secures Positive EU Opinion",
      "id": 133184264,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly (NYSE:LLY) recently announced several significant events, including promising trial results for baricitinib in treating severe alopecia areata and long-term efficacy data for EBGLYSS in atopic dermatitis. Additionally, the European Medicines Agency's positive opinion on Jaypirca for chronic lymphocytic leukemia marks a critical milestone. Meanwhile, the company is expanding its manufacturing capacity with plans to build four new sites in the U.S., promising substantial job creation...",
      "url": "https://finnhub.io/api/news?id=5420be4a870c13079b65675b3cdfd6ee173bf6bb8e2c85ee7f971434d15bdf85"
    }
  },
  {
    "ts": null,
    "headline": "Amid Market Turmoil, Compelling Earnings Coming",
    "summary": "Investors looking for safe havens in a dangerous market. China EV players, FedEx and Micron earnings next week.",
    "url": "https://finnhub.io/api/news?id=872fca84d282f8da912d6da2335775c51c087e09e78f56152aafb7317d8cfeb5",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741963200,
      "headline": "Amid Market Turmoil, Compelling Earnings Coming",
      "id": 133174328,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/579977893/image_579977893.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Investors looking for safe havens in a dangerous market. China EV players, FedEx and Micron earnings next week.",
      "url": "https://finnhub.io/api/news?id=872fca84d282f8da912d6da2335775c51c087e09e78f56152aafb7317d8cfeb5"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Reverses Its Recent Upswing On Broader Market Woes. Is It A Sell?",
    "summary": "Eli Lilly stock has sold off alongside the broader market over the last week, undercutting its moving averages. Is LLY stock a sell?",
    "url": "https://finnhub.io/api/news?id=1abe98a94a5099519afa678fad5327d6aa411241faf00be9fb4307183a812db2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741961322,
      "headline": "Eli Lilly Reverses Its Recent Upswing On Broader Market Woes. Is It A Sell?",
      "id": 133184265,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly stock has sold off alongside the broader market over the last week, undercutting its moving averages. Is LLY stock a sell?",
      "url": "https://finnhub.io/api/news?id=1abe98a94a5099519afa678fad5327d6aa411241faf00be9fb4307183a812db2"
    }
  },
  {
    "ts": null,
    "headline": "Anat Ashkenazi",
    "summary": "Anat Ashkenazi",
    "url": "https://finnhub.io/api/news?id=c45031300586367cc9629613300532a1bfd53bd1b327ba7e53a62cd7d6124531",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741949280,
      "headline": "Anat Ashkenazi",
      "id": 133170050,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Anat Ashkenazi",
      "url": "https://finnhub.io/api/news?id=c45031300586367cc9629613300532a1bfd53bd1b327ba7e53a62cd7d6124531"
    }
  },
  {
    "ts": null,
    "headline": "Billionaire Ken Griffin More Than Doubled His Stake In This Market-Beating Growth Stock",
    "summary": "One of them had to do with Citadel's position in the pharmaceutical giant Eli Lilly (NYSE: LLY).  Ken Griffin and his team increased their stake in this leading drugmaker by 184%.  Should investors follow Griffin's lead and buy (more) shares of Eli Lilly?",
    "url": "https://finnhub.io/api/news?id=80cfe7b2533df99cb50616bfad1d21f750a368ec9960dce2f567bc6bf27890fb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741947300,
      "headline": "Billionaire Ken Griffin More Than Doubled His Stake In This Market-Beating Growth Stock",
      "id": 133184266,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "One of them had to do with Citadel's position in the pharmaceutical giant Eli Lilly (NYSE: LLY).  Ken Griffin and his team increased their stake in this leading drugmaker by 184%.  Should investors follow Griffin's lead and buy (more) shares of Eli Lilly?",
      "url": "https://finnhub.io/api/news?id=80cfe7b2533df99cb50616bfad1d21f750a368ec9960dce2f567bc6bf27890fb"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals Has Lost Its Way, But Can It Find It Again?",
    "summary": "Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for more on REGN stock news.",
    "url": "https://finnhub.io/api/news?id=5b375f110a67ecf83936bf4bee953fea25a4043611ffce7bcba7609d1cc03b8c",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741945228,
      "headline": "Regeneron Pharmaceuticals Has Lost Its Way, But Can It Find It Again?",
      "id": 133168922,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/168166178/image_168166178.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for more on REGN stock news.",
      "url": "https://finnhub.io/api/news?id=5b375f110a67ecf83936bf4bee953fea25a4043611ffce7bcba7609d1cc03b8c"
    }
  },
  {
    "ts": null,
    "headline": "Q4 Earnings Recap: Supernus Pharmaceuticals (NASDAQ:SUPN) Tops Branded Pharmaceuticals Stocks",
    "summary": "As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at branded pharmaceuticals stocks, starting with Supernus Pharmaceuticals (NASDAQ:SUPN).",
    "url": "https://finnhub.io/api/news?id=69f320a470a4404d3310a14540a67ad22f533ecb7fe437b1ed3f819aa2ec3b95",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741942874,
      "headline": "Q4 Earnings Recap: Supernus Pharmaceuticals (NASDAQ:SUPN) Tops Branded Pharmaceuticals Stocks",
      "id": 133184268,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at branded pharmaceuticals stocks, starting with Supernus Pharmaceuticals (NASDAQ:SUPN).",
      "url": "https://finnhub.io/api/news?id=69f320a470a4404d3310a14540a67ad22f533ecb7fe437b1ed3f819aa2ec3b95"
    }
  },
  {
    "ts": null,
    "headline": "An Ozempic successor falls short, Eli Lilly's GLP-1 pill, and senators grill RFK: Pharma news roundup",
    "summary": "An Eli Lilly exec said the company’s experimental weight-loss pill could make GLP-1 treatments more accessible worldwide, as it would be easier to manufacture and distribute globally. Three U.S. senators have demanded, in a letter, that Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. share details about several private dinners he attended with Donald Trump and healthcare executives at Mar-a-Lago. Novo Nordisk released clinical trial results on Monday for its potential Ozempic suc",
    "url": "https://finnhub.io/api/news?id=43812493fc5ec9fa1138e26a80992982ecc35c504b6bb28e56576f624f96d05d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741942800,
      "headline": "An Ozempic successor falls short, Eli Lilly's GLP-1 pill, and senators grill RFK: Pharma news roundup",
      "id": 133184269,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "An Eli Lilly exec said the company’s experimental weight-loss pill could make GLP-1 treatments more accessible worldwide, as it would be easier to manufacture and distribute globally. Three U.S. senators have demanded, in a letter, that Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. share details about several private dinners he attended with Donald Trump and healthcare executives at Mar-a-Lago. Novo Nordisk released clinical trial results on Monday for its potential Ozempic suc",
      "url": "https://finnhub.io/api/news?id=43812493fc5ec9fa1138e26a80992982ecc35c504b6bb28e56576f624f96d05d"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk: Stock Plunges, But It May Be Time To Load Up",
    "summary": "Novo Nordisk faces formidable challenges from Eli Lilly and new rivals, but its first-mover advantage and expanded manufacturing capacity remain strong. Read more on NVO stock here.",
    "url": "https://finnhub.io/api/news?id=1c0fafef307df37fc0100b9823b84e6f5c530a327dd2b869dc6c0e1abc0c82a1",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741942800,
      "headline": "Novo Nordisk: Stock Plunges, But It May Be Time To Load Up",
      "id": 133168679,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2158305291/image_2158305291.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Novo Nordisk faces formidable challenges from Eli Lilly and new rivals, but its first-mover advantage and expanded manufacturing capacity remain strong. Read more on NVO stock here.",
      "url": "https://finnhub.io/api/news?id=1c0fafef307df37fc0100b9823b84e6f5c530a327dd2b869dc6c0e1abc0c82a1"
    }
  },
  {
    "ts": null,
    "headline": "Big Pharma Walked Away From Mental Health. Why Some Are Coming Back.",
    "summary": "Big Pharma Walked Away From Mental Health. Why Some Are Coming Back.",
    "url": "https://finnhub.io/api/news?id=09fc9b71abef4f1898d1cad28f6c7e5443fc822dcfa4ca598789ed5beccc563d",
    "source": "DowJones",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741930200,
      "headline": "Big Pharma Walked Away From Mental Health. Why Some Are Coming Back.",
      "id": 133170247,
      "image": "",
      "related": "LLY",
      "source": "DowJones",
      "summary": "Big Pharma Walked Away From Mental Health. Why Some Are Coming Back.",
      "url": "https://finnhub.io/api/news?id=09fc9b71abef4f1898d1cad28f6c7e5443fc822dcfa4ca598789ed5beccc563d"
    }
  }
]